DE60223279D1 - Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum - Google Patents

Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum

Info

Publication number
DE60223279D1
DE60223279D1 DE60223279T DE60223279T DE60223279D1 DE 60223279 D1 DE60223279 D1 DE 60223279D1 DE 60223279 T DE60223279 T DE 60223279T DE 60223279 T DE60223279 T DE 60223279T DE 60223279 D1 DE60223279 D1 DE 60223279D1
Authority
DE
Germany
Prior art keywords
anomalic
treatment
production
cell growth
substituted bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223279T
Other languages
English (en)
Other versions
DE60223279T2 (de
Inventor
David H B Ripin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
OSI Pharmaceuticals LLC
Original Assignee
Pfizer Inc
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc, OSI Pharmaceuticals LLC filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE60223279D1 publication Critical patent/DE60223279D1/de
Publication of DE60223279T2 publication Critical patent/DE60223279T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60223279T 2001-11-30 2002-10-03 Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum Expired - Lifetime DE60223279T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33464701P 2001-11-30 2001-11-30
US334647P 2001-11-30
PCT/IB2002/004097 WO2003045939A1 (en) 2001-11-30 2002-10-03 Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
DE60223279D1 true DE60223279D1 (de) 2007-12-13
DE60223279T2 DE60223279T2 (de) 2008-05-29

Family

ID=23308141

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223279T Expired - Lifetime DE60223279T2 (de) 2001-11-30 2002-10-03 Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum

Country Status (28)

Country Link
US (1) US20030144506A1 (de)
EP (1) EP1448551B1 (de)
JP (1) JP4220388B2 (de)
KR (1) KR20040054813A (de)
CN (1) CN1639149A (de)
AR (1) AR037591A1 (de)
AT (1) ATE377009T1 (de)
AU (1) AU2002337428A1 (de)
BR (1) BR0214606A (de)
CA (1) CA2462149C (de)
DE (1) DE60223279T2 (de)
DO (1) DOP2002000519A (de)
ES (1) ES2295409T3 (de)
GT (1) GT200200245A (de)
HN (1) HN2002000334A (de)
HU (1) HUP0500117A3 (de)
IL (1) IL160971A0 (de)
MX (1) MXPA04005157A (de)
PA (1) PA8558601A1 (de)
PE (1) PE20030643A1 (de)
PL (1) PL370911A1 (de)
RS (1) RS44004A (de)
RU (1) RU2004116345A (de)
SV (1) SV2004001419A (de)
TN (1) TNSN02096A1 (de)
TW (1) TW200300691A (de)
WO (1) WO2003045939A1 (de)
ZA (1) ZA200402054B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303045A1 (en) * 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
BR0317259A (pt) * 2002-12-19 2005-11-08 Pfizer Prod Inc Complexos de e-2-metóxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-ilóxi)-fenil amino]- quinazolin-6-il}-alil)-acetamida, seus métodos de produção e utilização
RU2005125607A (ru) * 2003-04-09 2006-03-27 Пфайзер Продактс Инк. (Us) Способы получения производных n(пиридинилокси)-фениламино)хиназолинил)аллил)ацетамида и родственных соединений, а также промежуточные соединения для таких способов и способы получения таких соединений
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
UA85706C2 (en) * 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2635837A1 (en) * 2005-12-02 2007-06-28 The Paper Products Limited Holographic flexible tube laminate for packaging and method of making the same
MX2021003517A (es) 2018-09-25 2021-08-16 Black Diamond Therapeutics Inc Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
SV2004001419A (es) 2004-02-24
JP2005515986A (ja) 2005-06-02
TW200300691A (en) 2003-06-16
DE60223279T2 (de) 2008-05-29
PE20030643A1 (es) 2003-07-23
ES2295409T3 (es) 2008-04-16
DOP2002000519A (es) 2003-05-31
MXPA04005157A (es) 2004-08-11
US20030144506A1 (en) 2003-07-31
EP1448551B1 (de) 2007-10-31
IL160971A0 (en) 2004-08-31
HN2002000334A (es) 2003-02-21
JP4220388B2 (ja) 2009-02-04
PA8558601A1 (es) 2003-06-30
CA2462149C (en) 2010-06-22
AR037591A1 (es) 2004-11-17
HUP0500117A3 (en) 2008-03-28
KR20040054813A (ko) 2004-06-25
RS44004A (en) 2006-10-27
PL370911A1 (en) 2005-05-30
WO2003045939A1 (en) 2003-06-05
EP1448551A1 (de) 2004-08-25
RU2004116345A (ru) 2005-03-27
CN1639149A (zh) 2005-07-13
CA2462149A1 (en) 2003-06-05
AU2002337428A1 (en) 2003-06-10
ATE377009T1 (de) 2007-11-15
HUP0500117A2 (hu) 2005-05-30
BR0214606A (pt) 2004-09-14
TNSN02096A1 (en) 2005-12-23
ZA200402054B (en) 2005-05-23
GT200200245A (es) 2003-09-24

Similar Documents

Publication Publication Date Title
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60323192D1 (de) Verfahren zur Herstellung von Hydroxyalkylstärkederivaten
DE502004001613D1 (de) Verfahren zur herstellung von polyamiden
DE50200540D1 (de) Verfahren zur Herstellung lösungsmittelfreier Suspensionen
DE60224643D1 (de) Verfahren zur herstellung von reifen
DE60302682D1 (de) Verfahren zur Herstellung von Nanopartikeln
DE50208864D1 (de) Verfahren zur herstellung von arylaminen
DE60225539D1 (de) Verfahren zur kontinuierlichen herstellung von polyarylensulfid
DE60208562D1 (de) Verfahren zur herstellung von tagatose
DE502004005626D1 (de) Verfahren zur herstellung von organoacylphosphiten
DE60223279D1 (de) Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum
DE60204334D1 (de) Verfahren zur herstellung von repaglinide
DE50311721D1 (de) Verfahren zur Herstellung von Aryl-aminopropanolen
DE50312095D1 (de) Verfahren zur herstellung hochfester polypropylenfasern
ATA218299A (de) Verfahren zur herstellung von oxindolen
DE60322356D1 (de) Verfahren zur herstellung von 2-aminoindanderivaten
DE60113157D1 (de) Verbessertes verfahren zur herstellung von simvastatin
DE60039688D1 (de) Verfahren zur herstellung von uhrarmbandteilen
ATA20122001A (de) Verfahren zur behandlung von cellulosischen formkörpern
DE60012337D1 (de) Verfahren zur herstellung von fluorcarbonsäureanyhydriden
DE60301444D1 (de) Verfahren zur Herstellung von Polyalkylphenoxyaminoalkanen
DE60318444D1 (de) Verfahren zur herstellung von nevirapin
DE602004023534D1 (de) Verfahren zur herstellung von optisch aktivem 2-alkylcystein, derivate davon und herstellungsverfahren
DE50008921D1 (de) Verfahren zur herstellung von blockweichschaumpolyolen
DE50306461D1 (de) Verfahren zur herstellung von ph-sonden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition